导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.06% | 3850/4587 |
| 近一周 | -2.23% | 3447/5248 |
| 近一月 | -5.43% | 3588/5205 |
| 近一季 | 4.53% | 373/5018 |
| 近半年 | -8.74% | 3395/4725 |
| 近一年 | -20.24% | 3804/4241 |
| 近两年 | 11.25% | 2700/2862 |
| 近三年 | -14.17% | 2000/2171 |
| 成立以来 | 107.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.56% 4238/4961 |
-9.00% 3936/5312 |
- - |
- - |
| 2025 | 4.93% 3021/4813 |
0.25% 1932/3635 |
-1.60% 3223/4076 |
16.13% 2711/4524 |
-8.40% 3916/4813 |
| 2024 | 0.13% 2085/3463 |
-2.88% 1449/2808 |
-7.95% 2148/3014 |
18.44% 1006/3129 |
-5.43% 2560/3463 |
| 2023 | -15.83% 1660/2656 |
-0.33% 1791/2280 |
-9.41% 2055/2385 |
-0.30% 413/2515 |
-6.49% 1804/2655 |
| 2022 | -18.72% 747/2207 |
-18.58% 1354/1919 |
12.90% 232/2016 |
-14.56% 1115/2113 |
3.49% 685/2208 |
| 2021 | -7.27% 1033/1822 |
-6.48% 1008/1255 |
10.04% 495/1330 |
-12.13% 1291/1466 |
2.54% 568/1822 |
| 2020 | 81.06% 38/1250 |
-0.08% 178/1028 |
26.83% 138/1067 |
19.81% 67/1164 |
19.24% 78/1184 |
| 2019 | 42.21% 218/1092 |
25.87% 440/754 |
2.40% 85/804 |
4.57% 193/850 |
5.51% 708/918 |
| 2018 | -23.53% 285/834 |
- - |
- - |
- - |
-16.50% 638/691 |
| 2017 | 31.12% 51/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.61% 224/605 |
- - |
- - |
- - |
- - |
| 2015 | 29.07% 79/575 |
- - |
- - |
- - |
- - |
| 2014 | 19.95% 193/237 |
- - |
- - |
- - |
- - |
| 2013 | 12.93% 37/186 |
- - |
- - |
- - |
- - |
| 2012 | 6.68% 67/140 |
- - |
- - |
- - |
- - |
| 2011 | -25.27% 74/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商上证消费80ETF VS. 长安沪深300非周期A(740101) |